$18.57
0.02[0.11%]
Last update: 8:30AM Get Real Time Here
Kiniksa Pharmaceuticals
(NASDAQ:KNSA)Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA), Analyst Ratings, Price Targets, Predictions
Kiniksa Pharmaceuticals Ltd has a consensus price target of $28.2, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from Evercore ISI Group, Wedbush, and Goldman Sachs on April 24, 2024, January 2, 2024, and July 26, 2023. With an average price target of $29 between Evercore ISI Group, Wedbush, and Goldman Sachs, there's an implied 55.79% upside for Kiniksa Pharmaceuticals Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
Wedbush
Goldman Sachs
JP Morgan
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Kiniksa Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | KNSA | Buy Now | Kiniksa Pharmaceuticals | $18.61 | 61.16% | Evercore ISI Group | Liisa Bayko | $25 → $30 | Maintains | Outperform | Get Alert |
| 01/02/2024 | KNSA | Buy Now | Kiniksa Pharmaceuticals | $18.61 | 34.3% | Wedbush | David Nierengarten | $23 → $25 | Maintains | Outperform | Get Alert |
| 07/26/2023 | KNSA | Buy Now | Kiniksa Pharmaceuticals | $18.61 | 71.9% | Goldman Sachs | Paul Choi | $22 → $32 | Maintains | Buy | Get Alert |
| 03/09/2023 | KNSA | Buy Now | Kiniksa Pharmaceuticals | $18.61 | 7.44% | JP Morgan | Anupam Rama | $19 → $20 | Maintains | Overweight | Get Alert |
| 12/29/2021 | KNSA | Buy Now | Kiniksa Pharmaceuticals | $18.61 | 82.65% | B of A Securities | Geoff Meacham | $37 → $34 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Kiniksa Pharmaceuticals (KNSA)?
The latest price target for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was reported by Evercore ISI Group on April 24, 2024. The analyst firm set a price target for $30.00 expecting KNSA to rise to within 12 months (a possible 61.55% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kiniksa Pharmaceuticals (KNSA)?
The latest analyst rating for Kiniksa Pharmaceuticals (NASDAQ: KNSA) was provided by Evercore ISI Group, and Kiniksa Pharmaceuticals maintained their outperform rating.
When was the last upgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last upgrade for Kiniksa Pharmaceuticals.
When was the last downgrade for Kiniksa Pharmaceuticals (KNSA)?
There is no last downgrade for Kiniksa Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Kiniksa Pharmaceuticals (KNSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kiniksa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kiniksa Pharmaceuticals was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating Kiniksa Pharmaceuticals (KNSA) correct?
While ratings are subjective and will change, the latest Kiniksa Pharmaceuticals (KNSA) rating was a maintained with a price target of $25.00 to $30.00. The current price Kiniksa Pharmaceuticals (KNSA) is trading at is $18.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.